Overview

Where the power of nature meets the logic of science for the betterment of health.
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals, chemistry and analytical testing services, and product regulatory and safety consulting. As a result of our relationships with leading universities and research institutions, we are able to discover and acquire early stage, ingredient technologies that are protected by intellectual property.... More »

Stock Quote
NASDAQ - CDXC
Price$6.65
Change (%) Stock is Up 0.02 (0.30%)
Volume189,745
Refresh quote
Real-Time Level 2 Quote
Recent NewsMore »
DateTitle 
11/09/17ChromaDex Reports Third Quarter 2017 Financial Results
- Company Reports Third Quarter 2017 Revenue of $6.1 Million, Up 55% Compared to Last Year - - Continued Progress on Building a Consumer Products Platform Around TRU NIAGEN™- IRVINE, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a science-based, fully integrated nutraceutical company devoted to extending human healthspan, announced today the financial results for the quarter ended September 30, 2017. Frank Jaksch, Jr., CEO and co-founder of ChromaDex commented, “T... 
Printer Friendly Version
11/06/17ChromaDex Announces $23 million Private Placement of Common Stock
Private Placement Led By High Profile Venture Capitalists and Strategic Investors IRVINE, Calif., Nov. 06, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a science-based, fully integrated nutraceutical company devoted to extending human healthspan, announced today that it has entered into a securities purchase agreement for the sale of approximately $23 million of its common stock in a private placement.  The private placement was led by high profile venture capitalists and internati... 
Printer Friendly Version
11/02/17ChromaDex to Report Third Quarter 2017 Financial Results on Thursday, November 9, 2017
-Company Will Host Investor Conference Call on Thursday, November 9, 2017- IRVINE, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a science-based, fully integrated nutraceutical company devoted to extending human healthspan, announced today that it plans on reporting its third quarter 2017 financial results on Thursday, November 9, after the close of the financial markets. ChromaDex management will host an investor conference call to discuss the quarterly results ... 
Printer Friendly Version
Upcoming EventsMore »

There are currently no events scheduled.

What's New
Download Documentation2017 Q3 Quarterly Report on Form 10Q
Download DocumentationSpecial Meeting – Proxy Statement
Download Documentation2017 Proxy Statement
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Chromadex Corp posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.